Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490931 · ClinicalTrials.gov registry record · Phase 4
Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients
A Phase 4 study, sponsored by Hersh, Elliot V., DMD, MS, PhD.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT01490931: Completed Phase 4 study, sponsored by Hersh, Elliot V., DMD, MS, PhD.
NCT01490931 is a Phase 4 study that has completed, run by Hersh, Elliot V., DMD, MS, PhD. The registered enrollment target is 28 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01490931, a Phase 4 study, has completed, sponsored by Hersh, Elliot V., DMD, MS, PhD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
The surgical placement of dental implants is presently a common procedure performed by oral surgeons, periodontists, and general dentists. The surgery can be performed under local anesthesia and involves the incision of soft tissue to expose the underlying bone, preparation of the implant site using a specialized surgical drill, and.screwing the implant into bone using a specialized headpiece. Dental implant patients experience postoperative pain yet there are no studies in the literature which have evaluated the efficacy of analgesics in this patient population. The current pilot study will evaluate the analgesic effects and tolerability of a recently FDA-approved analgesic formulation of intranasal ketorolac (SPRIX®) in 25 patients who have 1 - 3 dental implants surgically placed. Patients will self administer the ketorolac nasal spray (one spray in each nostril, 31.5 mg total dose) when their postoperative pain reaches at least a moderate severity. Pain intensity and pain relief scores will then be recorded every 20 minutes for the first hour, at 1.5 and 2 hours and then hourly through 6 hours on a validated analgesic diary. Side effects will be recorded when and if they occur. Patients will then transition to a multi-dose phase where they will be allowed to dose with ketorolac as indicated in the package insert (up to 4 times per day for 5 days). Patients will record the time of each dose, a daily assessment of overall efficacy and side effects, and the use of any rescue medication (acetaminophen 650 mg) on a take home diary.
Primary Outcome
Pain intensity scores will be recorded by patient employing a standard 100 mm visual analog scale
Interventions
- DRUG Ketorolac Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
What the finished NCT01490931 record still lists
NCT01490931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Ketorolac Nasal Spray is the first listed.
NCT01490931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01490931 about?
NCT01490931 is a clinical study titled "Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients". The surgical placement of dental implants is presently a common procedure performed by oral surgeons, periodontists, and general dentists. The surgery can be performed under local anesthesia and involves the incision of soft tissue to expose the underlying bone, preparation of the implant site using...
What is the current status of trial NCT01490931?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2011-11. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01490931?
The interventions under investigation include: Ketorolac Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT01490931?
This trial is sponsored by Hersh, Elliot V., DMD, MS, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01490931's enrollment target sits among peer trials
28 1635th of 2000 higher than 350 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia